|Year : 2014 | Volume
| Issue : 6 | Page : 949-951
Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India
Jeevan Malaiyan, Thatchayini Duraipandian, Aparna Warrier, Thangam Menon
Department of Microbiology, Dr. ALM PG Institute of Basic Medical Sciences University of Madras, Taramani Chennai 600 113, India
|Date of Web Publication||4-Aug-2014|
Department of Microbiology, Dr. ALM PG Institute of Basic Medical Sciences University of Madras, Taramani Chennai 600 113
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Malaiyan J, Duraipandian T, Warrier A, Menon T. Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India. Indian J Med Res 2014;139:949-51
|How to cite this URL:|
Malaiyan J, Duraipandian T, Warrier A, Menon T. Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India. Indian J Med Res [serial online] 2014 [cited 2020 May 24];139:949-51. Available from: http://www.ijmr.org.in/text.asp?2014/139/6/949/138084
Mumps is an acute, highly contagious, systemic, communicable viral infection found throughout the world, characterized by parotitis of one or both salivary glands. Although it is generally believed that mumps virus is serologically monotypic, distinct genetic lineages of wild-type mumps viruses have been described and reported to be co-circulating globally  . The introduction of MMR vaccine had led to a decline in the levels of measles, mumps and rubella infections. Recent reports suggest the re-emergence of mumps infections in the vaccinated populations  . It is proposed that this re-emergence is due to the poor efficacy of the mumps vaccine strain and circulation of a heterologous strain different from the vaccine strain  . We have recently reported mumps infection in MMR vaccine recipients in India and identified genotype C rather than the vaccine strain (genotype N)  . There is a paucity of data regarding mumps infection in India, except for a few studies which have assessed the efficiency of MMR vaccine ,,. The present study was aimed to screen the rate of vaccine induced IgG seropositivity among healthy MMR vaccinees and to determine the peak antibody level.
This study was conducted between February 2011 and December 2012 in the Department of Microbiology, Dr. ALM institute of Basic Medical Sciences, Chennai, Tamil Nadu, India. MMR vaccinated healthy children, adolescents and adults aged 2 to 25 years were selected randomly from Sri Ramachandra Medical College & Research Institute and V. K. Nursing Home, Chennai, India. An informed written consent and details including name, sex, date of birth, status and date of MMR immunization, past history suggestive of measles, mumps or rubella infection were obtained. Only those subjects who received one dose (15 th month) and two doses (15 th month and 5 th yr) of MMR vaccine were included in the study. Human ethical clearance was obtained from Sri Ramchandra Medical College & Research Institute and Dr. ALM PG Institute of Basic Medical Sciences as per the study protocol. Blood sample (3 ml) was collected from each study participant and serum was separated and stored at -86°C until use. Participants having a history of receiving prolonged steroid therapy, convulsions or epilepsy, having received another live vaccine within the last four weeks, those who received blood, plasma or immunoglobulin within the last three months, those diagnosed with malignancy or immunodeficiency diseases or those with a history of severe reactions to a previous dose of MMR vaccine were excluded from the study. Measles, mumps and rubella specific quantitative IgG EIA (Techno Genetics, Italy) was done to quantify MMR induced specific IgG antibody to confirm that they had been vaccinated. IgG antibody titres of > 115 mU/ml for mumps, > 115 mIU/ml for measles and >15 IU/ml for rubella were defined as seropositivity  . Data were analyzed by means of One-way and Two-way ANOVA, non-parametric Brown-Forsythe test, p <0.05 was considered significant, and GraphPad Prism 6, version 6.01 (GraphPad Software, Inc, USA) was used.
A total of 12 individuals who had received a single dose and 95 individuals who had received two doses of MMR vaccine participated in this study; four of the 95 were excluded because of a doubtful history of previous infection. The participants were subdivided into four age groups: 2-5, 6-12, 13-18 and 19-25 yr. Of the 103 samples, highest seropositivity (100%) was noticed for rubella. The lowest rate of seropositivity was found for mumps (49 & 83%, for two doses and one dose, respectively). Seropositivity to measles was intermediate (76 & 92%, for two doses and one dose, respectively) suggesting that there was variation in antibody responses to the three different viruses. The seropositivity as detected by the presence of IgG antibody to mumps virus was significantly lower ( p <0.05) among all the age groups, compared with measles and rubella [Table 1]. The percentage of MMR recipients who developed a protective range of mumps IgG after one dose and two doses of the vaccine was more among females (100 & 70%, respectively) than males (71 & 33%, respectively) but IgG against measles was more among males (100 & 78%, respectively) than females (80 & 72%, respectively) and equal (100%) for rubella IgG. The median concentration of IgG antibodies was evaluated in different age groups and the persistence of antibody to MMR vaccine was at its peak in the 6-12 yr age group and declined in the later age for mumps and measles [Table 2].
|Table 2: Median concentration with range of IgG antibodies in MMR vaccinees|
Click here to view
Since December 2005, 110 (57%) of the 193 World Health Organization member s0 tates had included mumps vaccine in their national immunization programmes, by including the combined measles-mumps-rubella (MMR) vaccine , . MMR vaccine is not included in the Indian Immunization schedule and the Indian Academy of Pediatrics has suggested including two doses of an MMR vaccine in the immunization schedule  . In the last decade, mumps made a global resurgence irrespective of whether people were vaccinated with MMR or not. The failure of the available mumps vaccine in preventing disease transmission among populations with high two-dose vaccination coverage levels raises a question regarding the vaccine efficacy ,, . In India, there are reports of non-adherence to the vaccination schedule which is alarming considering all the complications associated with mumps , . In the present study, the presence of IgG antibody to mumps virus in a limited number of individuals was used as a measure of immunity against mumps in Chennai, India. The results showed that the MMR induced seropositivity to mumps was low which was similar to a report from Germany  . Our preliminary results also suggested absence of lifelong protection and consequent susceptibility to infection. Further studies with a large number of MMR vaccinees are needed to confirm the decline of mumps and measles antibody levels over time after MMR vaccination, and the possibility of maintaining seroprotective antibody by additional doses during adulthood needs to be investigated.
| Acknowledgment|| |
Authors thank Dr. Padmasani Venkat Ramanan, Department of Pediatrics, Sri Ramachandra Medical College & Research Institute, Porur, Chennai and Dr Srinivasan V, Dr. Chitra S, V.K. Nursing Home, Valasaravakkam, Chennai, India for assistance in identifying the MMR recipients.
| References|| |
|1.||World Health Organization. Mumps virus nomenclature update. Wkly e0 pidemiol r0 ec 2012; 87 : 217-24. |
|2.||Steven AR, Malen AL, Christian J, Cheryl Z, Laurie N, Bert KR, et al. Recent mumps outbreaks in vaccinated populations: No evidence of a immune escape. J Virol 2012; 86 : 615-20. |
|3.||Allwinn R, Zeidler B, Steinhagen K, Rohwäder E, Wicker S, Rabenau HF, et al. Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity? Eur J Clin Microbiol Infect Dis 2011; 30 : 1223-8. |
|4.||Jeevan M, Sambantham S, Thangam M. Characterization of mumps virus genotype C among the patients with mumps in India. Indian J Med Microbiol 2013; 31 : 290-312. |
|5.||Dubey AP, Banerjee S. Measles, mumps, rubella (MMR) vaccine. Indian J Pediatr 2003; 70 : 579-84. |
|6.||Sunil G, Shilpa KA, Shukla D, Ramachandran VG. Immune response to second dose of MMR vaccine in Indian children. Indian J Med Res 2011; 134 : 302-6. |
|7.||Raut SK, Kulkarni PS, Phadke MA, Jadhav SS, Kapre SV, Dhere RM, et al. Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India. Clin Vaccine Immunol 2007; 14 : 1370-1. |
|8.||Chakravarti A, Yadav S, Berry N, Rastogi A, Mathur MD. Evaluation of serological status of rubella and mumps in children below five years. Indian J Med Res 1999; 110 : 1-3. |
|9.||Preeta KK, Deanna MKM, Gustavo HD, James PA, Nobia JW, Philip EG, et al. Seroprevalence of antibody to mumps virus in the US population, 1999-2004. J Infect Dis 2010; 202 : 667-74. |
|10.||Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices, Vashishtha VM, Kalra A, Bose A, Choudhury P, Yewale YN, et al. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India 2013 and updates on immunization. Indian Pediatr 2013; 50 : 1095-108. |
|11.||Echevarria JE, Castellanos A, Sanz JC, Martinez de Aragon MV, Pena Rey I, Mosquera M, et al. Mumps virus genotyping: Basis and known circulating genotypes. Open Vaccine J 2010; 3 : 37-41. |
|12.||Immunization Schedule. Department of p0 ublic h0 ealth & p0 reventive medicine, Health and f0 amily w0 elfare d0 epartment, Government of Tamil n0 adu. Available from: http://www.tnhealth.org/dphis.htm., November 3, 2010. |
|13.||Geeta MG, Krishna Kumar P. Mumps - need for urgent action. Indian Pediatr 2004; 41 : 1181-2. |
|14.||Poethko-Müller C, Mankertz A. Seroprevalence of measles, mumps and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One 2012; 7 : e42867. |
[Table 1], [Table 2]